1. United States
2. Mich.
3. Letter

Ambetter Insurance, owned by Centene, has quietly stripped hormone replacement therapy coverage from trans patients across 19 states — with no public announcement and no notice to affected customers. You need to investigate this and push for accountability. This isn't a policy disagreement; it's a company hiding a decision that is forcing people off life-sustaining medication. The policy change is documented. Ambetter's website was quietly updated on February 24th to exclude trans men from testosterone coverage in those 19 states. Superior Healthplan, Ambetter's Texas sister company, simply retired its gender affirming care policy on May 14 with no replacement. Customers started receiving denials in April with no explanation and no appeal information. Centene, the largest Medicaid and Medicare insurer in the country, donated $50,000 to Trump's Inauguration Fund and its executives are publicly aligning with the MAHA movement. The FDA is simultaneously expanding testosterone access for cis men. The double standard is not subtle. HRT prevents osteoporosis, hormonal collapse, and forced detransition for people whose bodies no longer produce hormones on their own. Denying it isn't a coverage technicality — it causes serious, lasting harm. Only 24 states and DC have meaningful trans healthcare protections. The people losing coverage right now have nowhere else to turn. Hold Centene accountable for what it's doing to its customers.